ADME/Tox Technologies Market Report
By Research Impact Technologies
Global Industry Analysis Market Research Report on ADME/Tox Technologies
– RI Technologies believes in pure research that will trigger action for immediate customer needs rather than plain reporting of data.
For Discount Queries –
contactus@researchimpact.com
This report on ADME/Tox Technologies gives a market insight into products and services used in the ADME/Tox industry. Predictive technologies analyzed include In vivo, In vitro, and In silico. Related technologies such as High Throughput Screening (HTS), Laboratory Information Management System (LIMS), and cell based assays are also analyzed. Market projections and estimates are illustrated by region and by technology. The report serves as a guide to ADME/Tox industry, covering more than 280 companies that are engaged in ADME/Tox studies/screening, products and services. Major Contract Research Organizations, Research Institutes and Universities serving the ADME/Tox industry are also covered in the corporate directory section of this report. Information related to recent product releases, product developments, partnerships, collaborations, and mergers and acquisitions is covered in the report. Compilation of Worldwide Patents related to ADME/Tox Technologies is also provided. A global perspective is presented along with regional analysis covering the regions of North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa with 92 exclusive graphically represented exhibits.
Global ADME/Tox Technologies market is projected to grow at a robust rate mainly driven by the efforts of pharmaceutical and biotech companies for reducing time and cost of drug discovery. ADME/Tox profiling of a drug candidate plays a key role in reducing clinical trials cost and time of drug launch to the market. ADME/Tox assays eliminate compounds with lack of bioavailability, lower efficacy and toxicity in early stages, in order to save time and costs in expensive later stages of drug discovery. Due to ethical issues and growing trend towards decrease in using animals in clinical trials, there is a gradual decline in market for In vivo predictive technology. Though In vivo accounts for about three- fourth of total ADME/Tox Technologies market currently, non-animal technologies- In vitro and In silico are projected to peg more than 40% of the market by 2022. In particular, In silico is projected to grow at a high CAGR during the period 2010-2022. In terms of technology, In silico is projected to register the fastest growth rate in all geographic markets. ADME/Tox report is an ideal research tool providing strategic business intelligence to the corporate sector.
This chapter provides information regarding the research methodology, limitations of the study, market measuring units and exchange rates used.
Synopsis of the report summarizes the global market, by ADME/Tox Technologies - In vivo, In vitro and In silico. A List of major companies by technology is also provided.
Market Dynamics chapter provides information on global markets for ADME/Tox Technologies. The chapter includes global market analysis (in US$) by geographic region; analysis of each region by both technology and product segment; Global LIMS, HTS, Market Dynamics chapter provides information on global markets for ADME/Tox Technologies. The section includes key market trends and an industry outlook.
Global market is also analyzed by geographic regions including North America, Europe, Asia-Pacific and Rest of World. The chapter provides market values (2010 -2022) in US$ for each geographic region including the US, Canada, UK, Germany, France, Sweden, Finland, Italy, Russia, Japan, China, India, South Korea, Australia, Brazil, Israel and South Africa.
This chapter of the report, provides comprehensive information regarding major global companies in the ADME/Tox market, including brief business profiles of major global companies; and a report of corporate activities such as mergers and acquisitions, partnerships, new product developments/launches, etc.
This chapter gives an insight into ADME/Tox Technologies market including definitions, segmentation and applications. The chapter also includes product trends and potential opportunities. Various ADME/Tox Methods, Toxicity types, and the importance of ADME/Tox in pharmaceutical industry and drug discovery process, and the challenges faced by the industry are also discussed. Various research activities in the field of ADME/Tox finds a mention in this chapter.
This chapter provides a global region-wise list of 350 plus companies, CROs and academic institutions that offer ADME/Tox products and/or services.
This chapter provides a compilation of worldwide patents related to ADME/Tox products/services.
Advanced Chemistry Development, Inc. (ACD Labs) (Canada)
Agilent Technologies, Inc. (USA)
Albany Molecular Research, Inc. (USA)
Bayer Technology Services GmbH (Germany)
Bio-Rad Laboratories, Inc. (USA)
BioreclamationIVT (USA)
BIOVIA (USA)
Cerep SA (France)
Certara LP (USA)
Charles River Laboratories, Inc. (USA)
Chenomx, Inc. (Canada)
CompuDrug International, Inc. (USA)
Corning, Inc. (USA)
Cyprotex plc (UK)
EMD Millipore (USA)
Envigo (UK)
Eurofins Scientific SE (France)
GE Healthcare Life Sciences (UK)
Gene Logic, Inc. (USA)
GenPharmTox BioTech AG (Germany)
ID Business Solutions Ltd. (UK)
Kibron, Inc. (Finland)
Korea Institute of Toxicology (South Korea)
LHASA Ltd. (UK)
Molecular Discovery Ltd. (UK)
MultiCASE, Inc. (USA)
Perkin Elmer, Inc. (USA)
Pharmaron (USA)
Promega Corporation (USA)
Schrodinger LLC (USA)
Sciex (USA)
Sekisui Medical Co., Ltd. (Japan)
Simulations Plus, Inc. (USA)
Sirius Analytical Instruments Ltd. (UK)
Sovicell GmbH (Germany)
Strand Life Sciences Pvt. Ltd. (India)
Taconic Biosciences, Inc. (USA)
Tecan Group Ltd. (Switzerland)
TetraQ (Australia)
Thermo Fisher Scientific, Inc. (USA)
Waters Corporation (USA)
WuXi AppTec Co., Ltd. (China)
Xceleron Ltd. (UK)
1. SCOPE AND METHODOLOGY
1.1 Scope of the Study
1.2 Research Methodology
1.3 Units and Currency
2. REPORT SYNOPSIS
2.1 ADME/Tox Technologies
Absorption
Distribution
Metabolism
Excretion
Toxicity
2.2 Significant Methods for ADME/Tox
Predictive Technologies
Related ADME/Tox Methods
2.3 ADME/Tox Technologies - Global Market Analysis
Exhibit 1. ADME/Tox Technologies - Global Market - Historic, Current, and Forecast (2010-2022) in US$ Billion
Exhibit 2. Major Global Companies in ADME/TOX Technologies Market
3. MARKET DYNAMICS
3.1 Market Overview
3.2. Global ADME/Tox Technologies Market Analysis
Exhibit 3. ADME/Tox Technologies - Global Market - Historic, Current, and Forecast (2010-2022) for North America, Europe, Asia-Pacific, and Rest of World in US$ Million
Exhibit 4. ADME/Tox Technologies - Global Market Shares (2012, 2018 & 2022) for North America, Europe, Asia-Pacific, and Rest of World
3.3 North American ADME/Tox Technologies Market Analysis
Exhibit 5. ADME/Tox Technologies - North American Market - Historic, Current, and Forecast (2010-2022) for United States and Canada in US$ Million
Exhibit 6. ADME/Tox Technologies - North American Market Shares (2012, 2018 & 2022) for United States and Canada
3.3 (1) United States ADME/Tox Technologies Market
3.3 (II) Canadian ADME/Tox Technologies Market
Competitor Overview
3.4 European ADME/Tox Technologies Market Analysis
Exhibit 8. ADME/Tox Technologies - European Market - Historic, Current, and Forecast (2010-2022) for UK, Germany, France, Sweden, Finland, Italy, Russia and Rest of Europe in US$ Million
Exhibit 9. ADME/Tox Technologies - European Market Shares (2012, 2018 & 2022) for UK, Germany, France, Sweden, Finland, Italy, Russia and Rest of Europe
3.3 (1) United Kingdom ADME/Tox Technologies Market
3.4 (II) German ADME/Tox Technologies Market
3.4 (III) French ADME/Tox Technologies Market
3.4 (IV) Swedish ADME/Tox Technologies Market
3.4 (V) Finnish ADME/Tox Technologies Market
3.4 (VI) Italian ADME/Tox Technologies Market
3.4 (VII) Russian ADME/Tox Technologies Market
Analysis by Select Rest of Europe Countries
Exhibit 10. ADME/Tox Technologies - Rest of Europe Market - Historic, Current, and Forecast (2010-2022) for Switzerland, Hungary, Belgium, Austria, Spain, and Other European Countries in US$ Million
Exhibit 11. ADME/Tox Technologies - Rest of Europe Market Shares (2012, 2018 & 2022) for Switzerland, Hungary, Belgium, Austria, Spain, and Other European Countries
Competitor Overview
3.5 Asia-Pacific ADME/Tox Technologies Market Analysis
Exhibit 13. ADME/Tox Technologies - Asia-Pacific Market - Historic, Current, and Forecast (2010-2022) for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million
Exhibit 14. ADME/Tox Technologies - Asia-Pacific Market Shares (2012, 2018 & 2022) for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific
3.5 (I) Japanese ADME/Tox Technologies Market
3.5 (II) Chinese ADME/Tox Technologies Market
3.5 (III) Indian ADME/Tox Technologies Market
3.5 (IV) Australian ADME/Tox Technologies Market
3.5 (V) South Korean ADME/Tox Technologies Market
3.5 (VI) Rest of Asia-Pacific ADME/Tox Technologies Market
Analysis by Select Rest of Asia-Pacific Countries
Exhibit 15. ADME/Tox Technologies - Rest of Asia-Pacific Market - Historic, Current, and Forecast (2010-2022) for Singapore, Hong Kong and Other Asia-Pacific Countries in US$ Million
Exhibit 16. ADME/Tox Technologies - Rest of Asia-Pacific Market Shares (2012, 2018 & 2022) for Singapore, Hong Kong, and Other Asia-Pacific Countries
Competitor Overview
3.6 Rest of World ADME/Tox Technologies Market Analysis
Exhibit 18. ADME/Tox Technologies - Rest of World Market - Historic, Current, and Forecast (2010-2022) for Brazil, South Africa, Israel and Other Countries in US$ Million
Exhibit 19. ADME/Tox Technologies - Rest of World Market Shares (2012, 2018 & 2022) for Brazil, South Africa, Israel and Other Countries
3.6 (I) Brazilian ADME/Tox Technologies Market
3.6 (II) South African ADME/Tox Technologies Market
3.6 (III) Israeli ADME/Tox Technologies Market
Competitor Overview
3.7 In Vivo ADME/Tox - An Ever Growing Technology
3.7.1 Global In Vivo ADME/Tox Market Analysis
Exhibit 21. In Vivo ADME/Tox Technologies- Global Market - Historic, Current, and Forecast (2010-2022) for North America, Europe, Asia-Pacific, and Rest of World in US$ Million
Exhibit 22. In Vivo ADME/Tox Technologies - Global Market Shares (2012, 2018 & 2022) for North America, Europe, Asia-Pacific, and Rest of World
Exhibit 23. List of Global In Vivo ADME/Tox Companies
3.7.2 North American In Vivo ADME/Tox Market Analysis
Exhibit 24. In Vivo ADME/Tox Technologies- North American Market - Historic, Current, and Forecast (2010-2022) for United States and Canada in US$ Million
Exhibit 25. In Vivo ADME/Tox Technologies - North American Market Shares (2012, 2018 & 2022) for United States, and Canada
3.7.3 European In Vivo ADME/Tox Market Analysis
Exhibit 26. In Vivo ADME/Tox Technologies- European Market - Historic, Current, and Forecast (2010-2022) for UK, Germany, France, Sweden, Finland, Italy, Russia and Rest of Europe in US$ Million
Exhibit 27. In Vivo ADME/Tox Technologies - European Market Shares (2012, 2018 & 2022) for UK, Germany, France, Sweden, Finland, Italy, Russia and Rest of Europe
3.7.4 Asia-Pacific In Vivo ADME/Tox Market
Exhibit 28. In Vivo ADME/Tox Technologies- Asia-Pacific Market - Historic, Current, and Forecast (2010-2022) for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million
Exhibit 29. In Vivo ADME/Tox Technologies - Asia-Pacific Market Shares (2012, 2018 & 2022) for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific
3.7.5 Rest of World In Vivo ADME/Tox Market
Exhibit 30. In Vivo ADME/Tox Technologies- Rest of World Market - Historic, Current, and Forecast (2010-2022) for Brazil, South Africa, Israel, and Other Countries in US$ Million
Exhibit 31. In Vivo ADME/Tox Technologies- Rest of World Market Shares (2012, 2018 & 2022) for Brazil, South Africa, Israel, and Other Countries
3.8 In Vitro ADME/Tox - An Emerging Technology
3.8.1 Global In Vitro ADME/Tox Market Analysis
Exhibit 32. In Vitro ADME/Tox Technologies - Global Market - Historic, Current, and Forecast (2010-2022) for North America, Europe, Asia-Pacific, and Rest of World in US$ Million
Exhibit 33. In Vitro ADME/Tox Technologies - Global Market Shares (2012, 2018 & 2022) for North America, Europe, Asia-Pacific, and Rest of World
Exhibit 34. List of Major Global In Vitro ADME/Tox Companies
3.8.2 North American In Vitro ADME/Tox Market Analysis
Exhibit 35. In Vitro ADME/Tox Technologies- North American Market - Historic, Current, and Forecast (2010-2022) for United States and Canada in US$ Million
Exhibit 36. In Vitro ADME/Tox Technologies - North American Market Shares (2012, 2018 & 2022) for United States, and Canada
3.8.3 European In Vitro ADME/Tox Market Analysis
Exhibit 37. In Vitro ADME/Tox Technologies- European Market - Historic, Current, and Forecast (2010-2022) for UK, Germany, France, Sweden, Finland, Italy, Russia and Rest of Europe in US$ Million
Exhibit 38. In Vitro ADME/Tox Technologies - European Market Shares (2012, 2018 & 2022) for UK, Germany, France, Sweden, Finland, Italy, Russia and Rest of Europe
3.8.4 Asia-Pacific In Vitro ADME/Tox Market Analysis
Exhibit 39. In Vitro ADME/Tox Technologies- Asia-Pacific Market - Historic, Current, and Forecast (2010-2022) for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million
Exhibit 40. In Vitro ADME/Tox Technologies - Asia-Pacific Market Shares (2012, 2018 & 2022) for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific
3.8.5 Rest of World In Vitro ADME/Tox Market
Exhibit 41. In Vitro ADME/Tox Technologies- Rest of World Market - Historic, Current, and Forecast (2010-2022) for Brazil, South Africa, Israel and Other Countries in US$ Million
Exhibit 42. In Vitro ADME/Tox Technologies- Rest of World Market Shares (2012, 2018 & 2022) for Brazil, Israel, South Africa, and Other Countries
3.9 In Silico ADME/Tox - The Fastest Growing Technology
3.9.1 Global In Silico ADME/Tox Market Analysis
Exhibit 43. In Silico ADME/Tox Technologies - Global Market - Historic, Current, and Forecast (2010-2022) for North America, Europe, Asia-Pacific, and Rest of World in US$ Million
Exhibit 44. In Silico ADME/Tox Technologies - Global Market Shares (2012, 2018 & 2022) for North America, Europe, Asia-Pacific, and Rest of World
Exhibit 45. List of Major Global In Silico ADME/Tox Companies
3.9.2 North American In Silico ADME/Tox Market Analysis
Exhibit 46. In Silico ADME/Tox Technologies- North American Market - Historic, Current, and Forecast (2010-2022) for United States and Canada in US$ Million
Exhibit 47. In Silico ADME/Tox Technologies - North American Market Shares (2012, 2018 & 2022) for United States, and Canada
3.9.3 European In Silico ADME/Tox Market Analysis
Exhibit 48. In Silico ADME/Tox Technologies- European Market - Historic, Current, and Forecast (2010-2022) for UK, Germany, France, Sweden, Finland, Italy, Russia and Rest of Europe in US$ Million
Exhibit 49. In Silico ADME/Tox Technologies - European Market Shares (2012, 2018 & 2022) for UK, Germany, France, Sweden, Finland, Italy, Russia and Rest of Europe
3.9.4 Asia-Pacific In Silico ADME/Tox Market Analysis
Exhibit 50. In Silico ADME/Tox Technologies- Asia-Pacific Market - Historic, Current, and Forecast (2010-2022) for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million
Exhibit 51. In Silico ADME/Tox Technologies - Asia-Pacific Market Shares (2012, 2018 & 2022) for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific
3.9.5 Rest of World In Silico ADME/Tox Market Analysis
Exhibit 52. In Silico ADME/Tox Technologies- Rest of World Market - Historic, Current, and Forecast (2010-2022) for Brazil, South Africa, Israel, and Other Countries in US$ Million
Exhibit 53. In Silico ADME/Tox Technologies- Rest of World Market Shares (2012, 2018 & 2022) for Brazil, South Africa, Israel, and Other Countries
3.10 Related Technologies
3.10.1 Laboratory Information Management Systems
Exhibit 54. Laboratory Information Management System (LIMS) - Global Market - Historic, Current, and Forecast (2010-2022) in US$ Million
3.10.2 High Throughput Screening
3.10.2.1 Global HTS Market Analysis
Exhibit 55. High Throughput Screening (HTS) - Global Market - Historic, Current, and Forecast (2010-2022) for United States, Europe, Asia-Pacific, Canada and Rest of World in US$ Million
Exhibit 56. High Throughput Screening (HTS) - Global Market Shares (2012, 2018 & 2022) for United States, Europe, Asia-Pacific, Canada and Rest of World
3.10.2.2 Global HTS Products Market Analysis
Exhibit 57. HTS Products - Global Market - Historic, Current, and Forecast (2010-2022) in US$ Million
3.10.2.3 Global Market Analysis for Re-Screening of Hits
Exhibit 58. Re-Screening of Hits - Global Market - Historic, Current, and Forecast (2010-2022) in US$ Million
3.10.2.4 Global Market Analysis for HTS Services and Consumables
Exhibit 59. HTS Services and Consumables - Global Market - Historic, Current, and Forecast (2010-2022) in US$ Billion
3.10.2.5 Global Market Analysis for HTS Services and Cell Based Consumables
Exhibit 60. HTS Services and Cell Based Consumables - Global Market - Historic, Current, and Forecast (2010-2022) in US$ Billion
3.10.2.6 Global Spending on HTS for Lead Discovery
Exhibit 61. Spending on HTS for Lead Discovery - Global Market - Historic, Current, and Forecast (2010-2022) for United States, Europe, and Rest of World in US$ Billion
3.10.2.7 US Spending on HTS for Lead Discovery
Exhibit 62. Spending on HTS for Lead Discovery- United States Market - Historic, Current, and Forecast (2010-2022) in US$ Billion
3.10.2.8 European Spending on HTS for Lead Discovery
Exhibit 63. Expenditure on HTS for Lead Discovery - European Market - Historic, Current, and Forecast (2010-2022) in US$ Billion
3.10.3 Cell Based Assays
3.10.3.1 Global Market Analysis for Cell Based Assays
Exhibit 64. Cell-Based Assays - Global Market - Historic, Current, and Forecast (2010-2022) for United States, Europe, Asia-Pacific, Canada and Rest of World in US$ Million
Exhibit 65. Cell-Based Assays - Global Market Shares (2012, 2018 & 2022) for United States, Europe, Asia-Pacific, Canada and Rest of World
3.10.3.2 Global Pharmaceutical Cell Based Screening Market Analysis
Exhibit 66. Pharmaceutical Cell-Based Screening - Global Market - Historic, Current, and Forecast (2010-2022) in US$ Billion
3.10.4 Global Drug Discovery Market Analysis
3.10.4.1 Global Drug Discovery Expenditure
Exhibit 67. Drug Discovery Expenditure - Global Market - Historic, Current, and Forecast (2010-2022) in US$ Billion
3.10.4.2 US Market Analysis for Pharma Contract Research
Exhibit 68. Pharmaceutical Contract Research - United States Market - Historic, Current, and Forecast (2010-2022) in US$ Billion
Exhibit 69. Number of Approved Drugs in the United States as of 2014
3.10.4.3 European Market Analysis for Drug Discovery
Exhibit 70. Drug Discovery - European Market - Historic, Current, and Forecast (2010-2022) in US$ Billion
3.10.4.4 European Market Analysis for Drug Discovery Outsourcing
Exhibit 71. Drug Discovery Outsourcing - European Global Market - Historic, Current, and Forecast (2010-2022) in US$ Billion
3.10.4.5 European Market Analysis for Nanotechnology Based Drug Discovery
Exhibit 72. Drug Discovery Based Nanotechnology - European Market - Historic, Current, and Forecast (2010-2022) in US$ Billion
3.10.4.6 Asia-Pacific Market Analysis for Drug Discovery
Drug Discovery Scenario in Asia-Pacific
Exhibit 73. Drug Discovery- Asia-Pacific Market - Historic, Current, and Forecast (2010-2022) in US$ Billion
3.10.4.7 Asia-Pacific Market Analysis for Pharma CROs
Exhibit 74. Pharmaceutical Contract Research Organization - Asia-Pacific Market - Historic, Current, and Forecast (2010-2022) in US$ Billion
3.10.5 Global Biotech Industry at a Glance
3.10.5.1 Major Research Areas in Biotechnology
Exhibit 75. Global Biotechnology Industry (2012): Percentage Breakdown of Major Research Areas
3.10.5.2 Canadian Market for Biotech R&D
Exhibit 76. Biotechnology R&D Expenditure - Canadian Market - Historic, Current, and Forecast (2010-2022) in US$ Billion
3.10.5.3 European Biotechnology Market
Exhibit 77. Biotechnology R&D Expenditure - European Market - Historic, Current, and Forecast (2010-2022) in US$ Billion
3.11 ADME/Tox Technologies - Market Outlook
Key Market Challenges
Other Side of the Coin
Key Market Drivers
4. COMPETITOR DYNAMICS
4.1 Company Profiles - Major Players in ADME/Tox Market
Advanced Chemistry Development, Inc. (ACD Labs) (Canada)
Agilent Technologies, Inc. (USA)
Albany Molecular Research, Inc. (USA)
Bayer Technology Services GmbH (Germany)
Bio-Rad Laboratories, Inc. (USA)
BioreclamationIVT (USA)
BIOVIA (USA)
Cerep SA (France)
Certara LP (USA)
Charles River Laboratories International, Inc. (USA)
Chenomx, Inc. (Canada)
CompuDrug International, Inc. (USA)
Corning, Inc. (USA)
Cyprotex plc (UK)
EMD Millipore (USA)
Eurofins Scientific SE (France)
GE Healthcare Life Sciences (UK)
Gene Logic, Inc. (USA)
GenPharmTox BioTech AG (Germany)
Harlan Laboratories, Inc. (USA)
ID Business Solutions Ltd. (UK)
Kibron, Inc. (Finland)
Korea Institute of Toxicology (South Korea)
LHASA Ltd. (UK)
Molecular Discovery Ltd. (UK)
MultiCASE, Inc. (USA)
Perkin Elmer, Inc. (USA)
Pharmaron (USA)
Promega Corporation (USA)
Schrodinger LLC (USA)
Sciex (USA)
Sekisui Medical Co., Ltd. (Japan)
Simulations Plus, Inc. (USA)
Sirius Analytical Instruments Ltd. (UK)
Sovicell GmbH (Germany)
Strand Life Sciences (India)
Taconic Farms, Inc. (USA)
Tecan AG (Switzerland)
TetraQ (Australia)
Thermo Fisher Scientific, Inc. (USA)
Waters Corporation (USA)
WuXi AppTec Co., Ltd. (China)
Xceleron Ltd. (UK)
4.2 Major Activities in ADME/Tox Market
AMRI Acquires Gadea Pharmaceutical Group
AMRI and PerkinElmer Enters into Drug Discovery Collaboration as Part of the Buffalo Medical Innovation and Commercialization Hub (BMIC)
Merck Inks Partnership Agreement with Organovo for Application of 3D Printed Liver System for Drug Testing
BioReliance In-Licenses Qualyst’s B-CLEAR® Technology for Drug Transporter Studies
Optivia Biotechnology and Hurel Corporation Enters into Technology and Marketing Collaboration
Schrödinger to Provide Computational Resources to Sanofi for Drug Discovery Programs
Taconic Strengthens Its Japanese Distribution and Breeding Collaborations
Cyprotex Establishes a High Throughput Laboratory in its US facility
ICON Acquires MediMedia Pharma Solutions
More…….
4.3 Major Product Introductions/Developments in ADME/Tox Market
Corning Life Sciences launches Corning® HepatoCells
PerkinElmer Launches Quantulus™ GCT and Tri-Carb® Systems to Expand Liquid Scintillation Counting Portfolio
AB SCIEX Unveils DiscoveryQuant™ 3.0 Software for Use in Sophisticated Pharmaceutical Laboratory
Sigma-Aldrich Introduces In-vitro ADME, Toxicology Assays
GENETWORx Receives Approval to Carryout Pharmacogenetic Testing in New York
Simulations Plus Unveils Version 7.0 of ADMET Predictor
More…..
5. PRODUCT/TECHNOLOGY RESEARCH
5.1 Introduction
ADME/Tox - The Basics
Absorption
Distribution
Metabolism
Metabolism of Drugs
Phases of Detoxification
Phase I-Modification
Oxidation
Reduction
NADPH-cytochrome P 450 Reductase
Reduced (ferrous) Cytochrome P 450
Hydrolysis
Phase II Conjugation
Phase III More Modification and Excretion
Factors Affecting Metabolism of Drugs
Excretion
Toxicity
Factors Determined by ADME/Tox
ADME/Tox Properties are determined by -
The Increasing Need to Predict ADME/Tox Profiles
Preclinical ADME/Tox Evaluation Tools
Some of the Current Evaluation Tools for ADME/Tox in Use Include -
Preclinical ADME/Tox Tools are generally validated for -
5.2 ADME/Tox - Essence of Pharmaceutical Industry
Drug Development - An Overview
Origin and Development of New Chemical Entity (NCE)
Process of Drug Development
Target Identification
Target Validation
Lead Identification
Technologies for Lead Generation
Common Technologies for Lead Generation Include -
Lead Optimization
Preclinical Trials
Technologies for Preclinical Development of Drug Candidates
Clinical Trials
Phase I
Phase II
Phase III
Exhibit 78. Drug Development Cost - Historic, Current, and Forecast (2010 - 2022) in US$ Million
Major hurdles in drug development process are:
Stages of Drug Development
Exhibit 79. Critical Path for a Drug to Enter Clinical Trials
Improved Technology Infrastructure Increases Potential of Manufacturing Efficiency
Exhibit 80. Estimated Time Required for Development of Drugs by Primary Indication (In Years)
5.3 ADME/Tox in Drug Discovery Process
Factors Influencing Drug Approval Rates
Ideally, a successful DMPK drug -
Estimating Potential R&D Efficiency Gains from an Improved Technology Infrastructure
Reasons for the Decline in Success Rates
Exhibit 81. Reasons for Drug Failure in Clinical Trials Phase I - III
5.4 ADME/Tox Methods
Predictive Technologies
Overlapping of Predictive ADME/Tox Technologies
Applications by Technology
Exhibit 82. Overlapping of Predictive ADME/Tox Technology Applications across Various Stages of Drug Discovery
Importance of In Vivo Tests
Exhibit 83. In Vivo ADME/Tox Methods
Modern In Vivo ADME/Tox Models
Zebrafish
Rodent Models
Drosophila
C.elegans
Conventional In Vivo ADME/Tox Models
Radiolabels
Cassette Dosing
Semi Simultaneous Dosing
Why do we Need Animals for Trials?
In Vitro ADMET
In Vitro Assays
Veterinary In Vitro Testing
Exhibit 84. Veterinary In Vitro Testing Technologies - Global Market - Historic, Current, and Forecast (2010-2022) in US$ Million
In Vitro Applications for Drug Discovery and Development
Human and Animal Metabolism
Permeation Studies
Other ADME Services
Exhibit 85. In Vitro ADME/TOX Methods
Examples of Human in Vitro ADME/Tox Assays Include
Biological Assay Systems for the Evaluation of Cytochrome P450 Enzyme Isoforms
In Silico ADMET
In Silico Applications along Preclinical Stages
In Silico Predictive Models
Broad Segmentation of In Silico Technology
Exhibit 86. In Silico ADME/Tox - Global Value Market - Historic, Current, and Forecast (2010-2022) for Organ and Tissue Cells, Cellular Networks, and Whole Cells in US$ Million
Applications of In Silico Models in Drug Discovery Process
Potential Applications of In Silico Technology
Prediction of In Silico Profiles by Metabolic Behavior
In Silico Technologies - Market Scenario
Prospects
Constraint
Related Technologies
Screening Technologies
The various types of screening technologies include
High Throughput Screening
Primary Screening
Secondary Screening
Biochemical Assays
Cell based Assays
High Content Screening
5.5 Toxicity
Toxicity - An Overview
Exhibit 87. Percentage of Toxicities Leading to Drug Failures in Clinical Trials (Phase I-III)
Toxicology - Reason for Drug Failure
Preclinical Toxicology
Predictive Toxicology
Methods and Challenges Involving Predictive Toxicology in Drug Discovery & Development
“Rule of Five”
ADME/Tox Models (Statistical Significance / Mechanistic Interpretation)
Challenges of ADME/Tox Prediction
Determining Factors for Effective Predictive Toxicology in Preclinical Stage
Remedial Measures
Types of Toxicities
Exhibit 88. Common Types of Toxicity Targeted for ADME/TOX Predictive Techniques
Hepatotoxicity or Drug Induced Liver Injury (DILI)
Metabolism of Drugs
Metabolism of Drug in Liver
Factors Resulting in Liver Damage
Drug Response
Future Prospects
Cardiotoxicity
Diagnosis
Cardiovascular Toxicity and QT Prolongation
Nephrotoxicity
Diagnosis
Neurotoxicity
Pulmonary Toxicity
Diagnosis
Pulmonary Toxicity Due to Medicinal Drugs
Pulmonary Toxicity Due to Radiation (Radiotherapy)
Pulmonary Toxicity Due to Chemical Compounds
Pulmonary Toxicity Due to Particulate Matter (cars, industry, etc)
Myotoxicity or Muscle Related Diseases
Dermatoxicity or Skin Related Allergies
Phototoxicity
Oculotoxicity
Reproductive Toxicity
Genotoxicity
Ames Testing to Confirm Genotoxicity
Genotoxicity and its Serious Impact on Regulatory Agencies
Hematotoxicity
Carcinogenicity
Cytotoxicity
Torsades de pointes
Exhibit 89. Common Approved In Vitro and In Vivo Procedures
Types of Predictive Toxicology
Computational Toxicology
QSAR
In Vitro Toxicology
Exhibit 90. Non-animal Methods being Considered for Validation
In Vitro Toxicology - Liver Cell Models
Tissue Culture Systems Used in In Vitro Toxicology
In Vitro Toxicology Applications
Genomics in Toxicity Testing
Examining Neurotoxicity
Alternatives for Animals in Toxicity Testing
Exhibit 91. Common Animals Used for ADME and Toxicity Testing
Exhibit 92. In vivo Animal Models for Toxicity Tests and their Importance
5.6 ADME/Tox and Drug Discovery Technologies
Pharmacogenomics
Pharmacokinetics
LADMET-R and Pharmacokinetics
ADME Associated Proteins
A - Category
D - Category
M - Category
E - Category
Exhibit 93. Classification of Protein Targets by Category
Proteomics
Bioinformatics
Challenges Facing the ADME/Tox Industry
5.7 ADME/Tox Technologies - Research Briefs
Computing Toxic Chemicals
Faster Smarter and Cheaper Drug Discovery
Novel Drug -Screening Process gives long sought anti-HIV compounds-Potential drugs acts on target that are not likely to mutate
Validation of the Preclinical efficacy of the TB drug target
Genomics of ADME
The edge of the drug development
More….
6. CORPORATE DIRECTORY
7. PATENTS
This report may help Strategists, Investors, Laboratories, Contract Research Organizations, Biotechnology & Healthcare Companies, Academic Professionals, Drug Approval Authorities, and Other Organizations to –
Analytics and data presented in each report pertain to several parameters such as –
Global ADME/TOX market is mainly driven by the efforts of pharmaceutical and biotech companies for reducing time and cost of drug discovery. ADME/Tox profiling of a drug candidate plays a key role in reducing clinical trials cost and time of drug launch to the market. ADME/Tox assays eliminate compounds with lack of bioavailability, lower efficacy and toxicity in early stages, in order to save time and costs in expensive later stages of drug discovery.
This ADME/Tox Market research report gives an insight into products and services used in the ADME/Tox industry. Predictive technologies analyzed include In vivo, In vitro, and In silico. Related technologies such as High Throughput Screening (HTS), Laboratory Information Management System (LIMS), and cell based assays are also analyzed. Market projections and estimates are illustrated by region and by technology. The report serves as a guide to ADME/Tox industry, covering more than 350 companies that are engaged in ADME/Tox Market size/screening, products and services. Major Contract Research Organizations, Research Institutes and Universities serving the ADME/Tox industry are also covered in the corporate directory section of this report. Information related to recent product releases, product developments, partnerships, collaborations, and mergers and acquisitions is covered in the report. Compilation of Worldwide Patents related to ADME/Tox Technologies is also provided. A global perspective is presented along with regional analysis covering the regions of North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa with 93 exclusive graphically represented exhibits. Key trends analyzed include ADME/TOX market growth, ADME Tox market potential, market shares, market aize, and other market critical factors. This ADME/Tox market research provides historical, current, and market forecasts.
The current study is quite useful in choosing the right technology at the right time to conduct ADME/Tox screening of a drug candidate, to save time and money in the process of obtaining regulatory approval. ADME/Tox is a science that needs to be better understood by strategic decision makers. The risks involved and the end use applications should be major areas of research going further. ADME/Tox is considered a major hurdle in drug discovery today. Companies that produce state-of- art tools and focus on complete solutions will be clear winners. Automation is the way to go with emphasis on lower costs. Clearly, animal models cannot be totally overruled owing to the traditional concerns, and also the comfort level involved since they provide the closest biological environment to human systems.
New technologies in ADME/Tox have evolved from diverse scientific disciplines. The toughest challenge is to integrate several successful features and enable pharmaceutical companies to benefit and reap profits in the future. Though some of the concepts in this industry are still in infant stages, the data generated from other relevant sources can be used to close the gaps. Pharmaceutical companies realize the potential of ADME/Tox technologies and are trying more than before to incorporate innovative procedures to reduce drug attrition rates and lessen the burden of costs and save precious time.
Strategic partnerships between pharmaceutical and biotechnology companies are the order of the day, and the trend is increasing globally. Another significant trend is the alliance between Pharma and Biotech companies and information technology companies such as Microsoft, IBM, Oracle, Sun, and Infosys, etc. The computer platforms generated by such companies help managing and analyzing the huge amounts of data produced from ADME/Tox technologies such as High Throughput Screening (HTS) and other computational techniques. Effective R&D strategy involves efficient data management and implementation plans. The new technologies promise improved efficacy, decreased toxicity in patients, and reduced time frames and expenditures.
